A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
Business
Archived
•
November 3, 2026
•
3 views
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Source: CNBC Top | https://search.cnbc.com/rs/search/combinedcms/view.xml?partnerId=wrss01&id=100003114 - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!


